Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT07918261

Evaluation of Fisetin to Reduce Systemic Senescence

Conditions: Cellular Senescence

Sex: All
Ages: 55 Years – N/A
Healthy volunteers: Yes
Phase: PHASE1, PHASE2
Enrollment: 82
Sponsor: Steadman Philippon Research Institute

Location: Steadman Philippon Research Institute Vail Colorado

Summary

This is a prospective, randomized clinical trial to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence (aging) indices assessed in peripheral blood.

Eligibility Criteria

Inclusion Criteria: * Adults ≥55 years of age; * Capacity to personally give informed consent (consent via legally authorized representative will not be accepted); * Willing to comply with all study procedures and assessments. Exclusion Criteria: * Within 2 years of signing informed consent history of active blood disorders (i.e., DVTs, chronic blood clotting, hemophilia, leukemia, myeloma, etc.); or active malignancy of any type or history of a malignancy (with the exception of Subjects with a history of treated basal or squamous cell carcinoma); * Females who are nursing a child, are pregnant, or are planning to become pregnant during drug dosing; * Males who do not wish to abstain from sex with women of childbearing potential without use of contraceptive protection by either party during drug dosing; * Any significant illness within the last 30 days requiring clinical care, and/or any medications, medical condition, including findings in medical history or in the baseline assessments that, in the opinion of the Principal Clinical Investigator or the screening clinician, constitutes a risk or contraindication for participation in the study or that could interfere with the study conduct, endpoint evaluation, or prevent the subject from fully participating in all aspects of the study; * Allergy to any active or inactive ingredient of Fisetin, and/or taking medication with known Fisetin interaction; * Subjects with any of the following drug/medication statuses: 1. Taking medications that affect insulin activity, including Metformin or Acarbose, within one week of signing informed consent; 2. Currently taking Warfarin or related anticoagulants; 3. Currently taking Lithium; 4. Senolytic agents taken within the past 3 months and are not willing to discontinue these medications through the duration of the study, including: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax; 5. Taking drugs that induce significant cellular stress and are not willing to discontinue these medications through the duration of the study, including alkylating agents, anthracyclines, platins, and other chemotherapy drugs; 6. Taking the following drugs if they cannot be held (per the Principal Investigator) for at least 2 days before and during administration of Fisetin: cyclosporine, tacrolimus, repaglinide, and bosentan; 7. Taking a glucocorticoid within 1 month of signing informed consent; 8. Currently taking phenytoin or nateglinide; * PHQ-9 - Patient Health Questionnaire - total score exceeds 9; * Inability to tolerate oral medication;

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07918261). StuddyBuddy aggregates publicly available trial information.